Evidence map›Paper›PMID 41629569›Full record

ArticleCommunications medicine2026

Cerebrospinal fluid cfDNA-based molecular assessment of resection extent and prognosis in glioma.

Jun Wu, Zhiqiang Liu, Tianxiang Huang, Ying Wang, Jian Yu, Shifu Li, Kang Xie, Shuwen Kuang, Chao Liu, Longbo Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jun WuDepartments of Neurosurgery, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Zhiqiang LiuDepartment of Neuroscience, Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0002-7579-6280
Tianxiang HuangDepartments of Neurosurgery, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Ying WangDepartments of Neurosurgery, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Jian YuDepartments of Neurosurgery, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Shifu LiDepartments of Neurosurgery, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Kang XieDepartments of Neurosurgery, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Shuwen KuangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Chao LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Longbo ZhangDepartments of Neurosurgery, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. zhanglb@csu.edu.cn.ORCID http://orcid.org/0000-0002-9077-3239

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGliomas, the most common brain tumors, present significant challenges in treatment, particularly glioblastoma multiforme (GBM), due to their infiltrative nature and difficulty in achieving gross total resection (GTR). Accurate assessment of surgical resection extent is critical for patient prognosis and survival. This study investigates the utility of cerebrospinal fluid (CSF) cell-free DNA (cfDNA) as a quantitative biomarker for evaluating glioma resection extent and patient prognosis.

methodsNext-generation sequencing (NGS) was used to profile genomic alterations in tumor DNA and CSF cfDNA obtained before and after surgery. Concordance between mutations detected in tumor tissue and CSF cfDNA was assessed. Post-operative changes in mean mutant allele frequency (MAF) and tumor mutational burden (TMB) were evaluated, and their associations with overall survival (OS) were analyzed.

resultsA high concordance rate (83.50%) exists between CSF cfDNA and tumor tissue, particularly for key somatic mutations such as TERT, TP53, PTEN, and IDH1. Post-operative cfDNA analysis shows a significant reduction in mean MAF and TMB. Apart from non-GTR and multiple lesions, patients who exhibit a ≥ 90% reduction in mean MAF or in the MAF of driver mutations post-surgery demonstrate significantly improved OS.

conclusionsThese findings suggest that CSF cfDNA effectively represents the genetic profile of gliomas and serves as a sensitive measure for surgical resection efficacy and patient prognosis, highlighting its potential as a non-invasive biomarker for enhancing post-operative management in glioma patients.

Identifiers

PMID41629569
PMCPMC13066638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.